Press Releases

Endometrial tumors can be reclassified into distinct subtypes based partly on their genomic makeup and may respond to targeted drugs already being tested in clinical trials, according to a large-scale genomic analysis led by researchers at Memorial Sloan-Kettering Cancer Center and other centers within The Cancer Genome Atlas Research Network.

In this new expanded role, Avice Meehan will streamline communications across the Center and lead both Memorial Sloan-Kettering’s Public Affairs and Marketing endeavors.

The experimental drug selumetinib may allow some patients with advanced thyroid cancer to overcome resistance to radioiodine (RAI), the most effective therapy for the disease, according to new research from Memorial Sloan-Kettering Cancer Center.

IBM, WellPoint, Inc., and Memorial Sloan-Kettering Cancer Center today unveiled the first commercially developed Watson-based cognitive computing breakthroughs. These innovations stand alone to help transform the quality and speed of care delivered to patients through individualized, evidence-based medicine.

Prostate cancer patients who are prescribed oral erectile medication before and after radiation therapy have improved sexual function, according to a research team at Memorial Sloan-Kettering Cancer Center.

New data reveals that women treated with radiation to the chest for childhood cancer have a high risk of developing breast cancer similar to that of women with BRCA1/2 mutations. The study, led by Memorial Sloan-Kettering Cancer Center biostatistician Chaya Moskowitz, PhD, was presented today at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.

Women on Long Island who don’t have insurance or who are underinsured may be able to take advantage of free mammograms at Memorial Sloan-Kettering Cancer Center Commack.

A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.

Researchers have identified a set of genetic abnormalities in patients with acute myelogenous leukemia (AML) that doctors can use to more accurately predict patients’ prognoses and select treatments that are most likely to benefit them. The study, led by investigators at Memorial Sloan-Kettering Cancer Center, will be published in the March 22 issue of the New England Journal of Medicine.